Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin

Background: The results of previous studies on the effect of low-dose aspirin in frozenthawed embryo transfer (FET) cycles are limited and controversial. Objective: To evaluate the effect of low-dose aspirin on the clinical pregnancy in the FET cycles. Materials and Methods: This study was performed as a randomized clinical trial from May 2018 to February 2019; 128 women who were candidates for the FET were randomly assigned to two groups receiving either 80 mg oral aspirin (n = 64) or no treatment. The primary outcome was clinical pregnancy rate and secondary outcome measures were the implantation rate, miscarriage rate, and endometrial thickness. Results: The endometrial thickness was lower in patients who received aspirin in comparison to the control group. There were statistically significant differences between the two groups (p = 0.018). Chemical and clinical pregnancy rates and abortion rate was similar in the two groups and there was no statistically significant difference. Conclusion: The administration of aspirin in FET cycles had no positive effect on the implantation and the chemical and clinical pregnancy rates, which is in accordance with current Cochrane review that does not recommend aspirin administration as a routine in assisted reproductive technology cycles. Key words: Aspirin, Embryo transfer, Pregnancy rates.

Download Full-text

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70)

American Journal of Cardiovascular Drugs ◽

10.1007/s40256-018-0313-0 ◽

2018 ◽

Vol 19 (3) ◽

pp. 299-311 ◽

Cited By ~ 1

Author(s):

Masahiro Sugawara ◽

◽

Yoshio Goto ◽

Tsutomu Yamazaki ◽

Tamio Teramoto ◽

...

Keyword(s):

Risk Factors ◽

Clinical Trial ◽

Cardiovascular Events ◽

Low Dose ◽

Japanese Patients ◽

Dose Aspirin ◽

Low Dose Aspirin ◽

Elderly Japanese ◽

Elderly Japanese Patients ◽

Atherosclerotic Risk Factors

Download Full-text

Effect of low-dose aspirin on the development of ovarian hyperstimulation syndrome and outcomes of assisted reproductive techniques in the women with PCOS, a randomized double-blinded clinical trial

Taiwanese Journal of Obstetrics and Gynecology ◽

10.1016/j.tjog.2019.01.016 ◽

2019 ◽

Vol 58 (2) ◽

pp. 255-260 ◽

Cited By ~ 2

Author(s):

Bahia Namavar Jahromi ◽

Jaleh Zolghadri ◽

Elham Rahmani ◽

Shohreh Alipour ◽

Zahra Anvar ◽

...

Keyword(s):

Clinical Trial ◽

Ovarian Hyperstimulation Syndrome ◽

Low Dose ◽

Assisted Reproductive Techniques ◽

Ovarian Hyperstimulation ◽

Dose Aspirin ◽

Low Dose Aspirin ◽

Reproductive Techniques ◽

Double Blinded

Download Full-text

Randomized clinical trial of preconception low dose aspirin use and pregnancy loss: results from the eager trial

Fertility and Sterility ◽

10.1016/j.fertnstert.2014.07.186 ◽

2014 ◽

Vol 102 (3) ◽

pp. e54

Author(s):

S.L. Mumford ◽

L.L. Lesher ◽

M.V. White ◽

N.J. Perkins ◽

E.F. Schisterman ◽

...

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Pregnancy Loss ◽

Low Dose ◽

Dose Aspirin ◽

Low Dose Aspirin

Download Full-text

Effect of Low Dose Aspirin in Low Risk Pregnant Ladies with Abnormal Uterine Artery Doppler Results, and the Evaluation of Maternal and Fetal outcomes: A Randomized Clinical Trial

Kurdistan Journal of Applied Research ◽

10.24017/science.2018.2.14 ◽

2018 ◽

pp. 85-89

Author(s):

Parzhin Jalal Ali ◽

Chro Najmaddin Fattah

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Uterine Artery ◽

Low Dose ◽

Low Risk ◽

The Other ◽

P Value ◽

Uterine Artery Doppler ◽

Dose Aspirin ◽

Low Dose Aspirin

This study aimed to identify the effect of low dose aspirin administration in low risk pregnant ladies who have abnormal uterine artery Doppler results. Patients and Methods: A randomized clinical trial was performed on 50 pregnant ladies (≥16 weeks of gestation) in Sulaymaniyah Maternity Teaching Hospital during January 2017 to January 2018. The participants were randomly enrolled into two groups; the participants in the first group were given 100 mg of aspirin tablet each but the other group was given nothing. Results: Preeclampsia was significantly (P-value of <0.001) less in the aspirin group as compared to the other group (16% and 40% respectively). The pulsatility index (PI) was not significantly different in both the groups (P-value = 0.69), but resistance index (RI) was significantly lower in the aspirin group (P-value of <0.001). Conclusion: Doppler study of the uterine artery at 16 weeks or higher in low risk pregnant women appears to be useful as a screening test and low dose of aspirin therapy at early stage of pregnancy will decrease the incidence of preeclampsia.

Download Full-text

Micro-simulation model to predict effects of low-dose aspirin on colorectal cancer, cardiovascular disease and safety outcomes among low-dose aspirin users

European Heart Journal ◽

10.1093/ehjci/ehaa946.3452 ◽

2020 ◽

Vol 41 (Supplement_2) ◽

Author(s):

K Bollaerts ◽

J Biccler ◽

V Pareen ◽

E Sole ◽

L.A Garcia Rodriguez ◽

...

Keyword(s):

Colorectal Cancer ◽

Cardiovascular Disease ◽

Simulation Model ◽

Low Dose ◽

Funding Source ◽

Peptic Ulcers ◽

Gi Bleeding ◽

Dose Aspirin ◽

Low Dose Aspirin ◽

Cvd Prevention

Abstract Background Regular use of low-dose aspirin (LDA) has been shown to reduce the risk of cardiovascular disease (CVD). Recent evidence indicates that regular LDA use also reduces the risk of colorectal cancer (CRC). Use of LDA has also been associated with an increased risk of gastrointestinal (GI) bleeding, peptic ulcers and intracranial hemorrhage (ICH). Purpose We aim to evaluate the population-level benefits and risks of daily and/or regular LDA among individuals taking LDA for primary or secondary CVD prevention in the United Kingdom (UK) accounting for the evidence on the reduced CRC risk. Methods Individual-level state transition modelling was used to predict the impact of LDA on CRC, CVD, safety events (GI bleeding, ICH and symptomatic peptic ulcers) and related deaths in a UK population. Individual event histories were simulated for hypothetical cohorts of 1 million adults aged 50–59 years and aged 60–69 years indicated to take LDA for primary or secondary CVD prevention. The QRISK CVD prediction score was used to simulate adults indicated to use LDA for CVD prevention. Model parameters were informed based on published scientific literature on CVD, CRC and safety outcomes mimicking the UK epidemiology and prevention guidelines. Monte Carlo simulation was used to account for parameter uncertainty. Results In the cohort of subjects for which low-dose aspirin use was initiated between 50–59 years, the decrease in incidence rates (IRs) (per 100,000person years) of non-fatal CVD was smaller when low-dose aspirin use was initiated for primary prevention compared to initiation for secondary prevention (−203 [95% UI, −277 to −115] versus −794 [95% UI, −997 to −536]). Similar results were obtained for fatal CVD (−97 [95% UI, −136 to −60] versus −381 [95% UI, −502 to −257]). Whether low-dose aspirin treatment was initiated for primary or secondary CVD prevention did not greatly influence the changes in the IR of the non-CVD outcomes. The changes in IR for fatal CRC were −46 [−69, −31] and −44 [−67, −26] for primary and secondary CVD prevention while the changes in IR for fatal bleeding were 5 [1, 9] and 5 [1, 10]. Similar results were obtained when low-dose aspirin use was initiated between 60–69 years. Conclusions In all simulation settings considered, low-dose aspirin related reductions in non-fatal and fatal CVD outcomes were larger in case of secondary CVD prevention compared to primary CVD prevention. These reductions were larger than the increases in fatal safety events. This favorable benefit-risk profile is more pronounced in the case of secondary CVD prevention. The results from the simulation model can be used to inform discussions with patients about the potential benefits and risk of LDA initiation. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Bayer AG

Download Full-text

Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial

Diabetes Care ◽

10.2337/dc19-1188 ◽

2019 ◽

Vol 43 (2) ◽

pp. 314-320 ◽

Cited By ~ 1

Author(s):

Chisa Matsumoto ◽

Hisao Ogawa ◽

Yoshihiko Saito ◽

Sadanori Okada ◽

Hirofumi Soejima ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Low Dose ◽

Follow Up Study ◽

Dose Aspirin ◽

Low Dose Aspirin ◽

Long Term Follow Up

Download Full-text

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study

Gut ◽

10.1136/gutjnl-2017-314852 ◽

2017 ◽

Vol 67 (6) ◽

pp. 1033-1041 ◽

Cited By ~ 19

Author(s):

Takashi Kawai ◽

Kazunori Oda ◽

Nobuo Funao ◽

Akira Nishimura ◽

Yasushi Matsumoto ◽

...

Keyword(s):

Peptic Ulcer ◽

Low Dose ◽

Extension Study ◽

Ulcer Recurrence ◽

Peptic Ulcers ◽

Gi Bleeding ◽

Double Blind ◽

Dose Aspirin ◽

Low Dose Aspirin

ObjectiveCompare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study.DesignDouble-blind, randomised, non-inferiority study; single-blind extension study at 104 Japanese sites, including 621 patients (439 in extension) with a history of peptic ulcers who required long-term LDA therapy. Randomised (1:1:1, computer generated) patients received lansoprazole 15 mg (n=217), vonoprazan 10 mg (n=202) or vonoprazan 20 mg (n=202) once daily for 24 weeks (double blind) and ≤2 years (extension). The following measurements were made: 24-week (primary outcome; double blind) and 12-week peptic ulcer recurrence rate, 24-week GI bleeding rate, cumulative incidences of peptic ulcer recurrence and GI bleeding, treatment-emergent adverse events, laboratory results, serum gastrin and pepsinogen I/II concentrations.ResultsThe 24-week peptic ulcer recurrence rate was 2.8%, 0.5% and 1.5% in the lansoprazole 15 mg, vonoprazan 10 mg and vonoprazan 20 mg groups, respectively. Vonoprazan was non-inferior (Farrington and Manning test: margin 8.7%, significance level 2.5%) to lansoprazole. In the post hoc analyses of the extension study, peptic ulcer recurrence rates were significantly lower with vonoprazan 10 mg (log-rank test, P=0.039), but not vonoprazan 20 mg (P=0.260), compared with lansoprazole 15 mg. GI bleeding rates were higher with lansoprazole compared with two doses of vonoprazan in both 24-week study and extension study.ConclusionVonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing peptic ulcer recurrence during LDA therapy, had a similar long-term safety profile and was well tolerated.Trial registration numbersNCT01452763; NCT01456247.

Download Full-text